Efficacy of first-line (1L) immunotherapy (IO)-based regimens in patients with sarcomatoid and/or rhabdoid (S/R) metastatic non-clear cell renal cell carcinoma (nccRCC): Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).Chris Labaki, Toni K. Choueiri, Kosuke Takemura et al.|Journal of Clinical Oncology|2023Cited by 4
Characterizing IMDC prognostic groups in contemporary first-line combination therapies for metastatic renal cell carcinoma (mRCC).Matthew Scott Ernst, Daniel Yick Chin Heng, Vishal Navani et al.|Journal of Clinical Oncology|2022Cited by 3